2025 Egyptian guidelines for the management of dyslipidemia. [PDF]
Egypt Heart JReda A +9 more
europepmc +1 more source
Rationale and Design of the EPISODE Trial: A Randomized Controlled Trial on the Effect of PCSK9 Inhibitors in Calcific Aortic Valve Stenosis. [PDF]
J Am Heart AssocZheng Y +6 more
europepmc +1 more source
Remnant cholesterol in chronic obstructive pulmonary disease-phenotypes and pharmacotherapy matter. [PDF]
J Thorac DisHao J, Gu X.
europepmc +1 more source
Genetic association between PCSK9 and coronary artery calcification mediated by inflammatory cytokines. [PDF]
Front Cardiovasc MedWang W +5 more
europepmc +1 more source
Association Between HNP1-3 and Atherosclerotic Plaque Burden in Subclinical Atherosclerosis and the Mediating Effect of PCSK9. [PDF]
Clin Transl SciYurtseven E +10 more
europepmc +1 more source
Reconciling Coronary Artery Calcification in the Lipid-Lowering Era. [PDF]
JACC AdvKhanna S, Nerlekar N, Bhat A.
europepmc +1 more source
Elevated Apolipoprotein B Is Associated With an Increased Risk of Adverse Outcomes in Aortic Stenosis. [PDF]
JACC AdvBansal A, Kapadia SR.
europepmc +1 more source
Genetic Pathogenesis of Abdominal Aortic Aneurysm and the Role of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9). [PDF]
Vasc Specialist IntChoi JY, Gwon JG.
europepmc +1 more source
Effect of Statins and PCSK9 Inhibition on Metabolic Dysfunction-Associated Steatotic Liver Disease. [PDF]
J Dig DisTheocharidou E, Gossios T.
europepmc +1 more source
Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease. [PDF]
BMC NephrolTang H +6 more
europepmc +1 more source